References
- Ginsberg J S, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 2001; 199: S122–S131
- American College of Obstetricians and Gynecologists. Prevention of deep vein thrombosis and pulmonary embolism. Washington, DC October 2000, ACOG Practice Bulletin, Number 21
- Andres R L, Miles A. Venous thromboembolism and pregnancy. Obstet Gynecol Clin North Am 2001 Sep; 28(3)613–630
- Enson M H, Stephenson M D. Low molecular weight heparins in pregnancy. Pharmacotherapy 1999; 19: 1013–1025
- Casele H L, Laifer S A, Woelkers D A, Venkataramanan R. Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol 1999; 181: 1113–1117
- Mayr A J, Dünser M, Jochberger S, Fries D, Klingler A, Joannidis M, Hasibeder W, Schobersberger W. Anti-factor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin. Thromb Research 2002; 105: 201–204
- Kessler C M, Esparraguera I M, Jacobs H M. Monitoring the anticoagulant effects of a low molecular weight heparin preparation: Correlation of assays in orthopedic surgery patients receiving ardeparin sodium for prophylaxis of deep venous thrombosis. Am J Clin Pathol 1995; 103: 642–650
- Kessler C M. Low molecular weight heparins: Practical considerations. Semin Hematol 1997; 34: 35–42
- Cunningham F G, Gant N F, Leveno K J, Gilstrap L C, Hauth J C, Wenstrom K D. Williams Obstetrics. 21st ed. McGraw–Hill, New York 2001